Course Details

MOLECULAR MEDICINE

Course Information

Semester	Course Unit Code	Course Unit Title	T+P+L	Credit	Number of ECTS Credits
5	MBG406	MOLECULAR MEDICINE	3+0+0	3	5

Course Details

Language of Instruction	English
Level of Course Unit	Bachelor's Degree
Department / Program	BIOENGINEERING
Type of Program	Formal Education
Type of Course Unit	Elective
Course Delivery Method	Face To Face
Objectives of the Course	This course will introduce new interdisciplinary area of study named “molecular medicine” that explores revolutionary developments in disease diagnosis, therapy and prevention, which is allowed by bio-molecular research.
Course Content	It shows how basic science is translated from ‘theory to the clinic.’ It covers advances in the personalised medicine that allowed the understanding of the disease mechanisms at cellular level, opening up new ways to treat major illnesses. The course’s main focus includes cancer, genetics, novel drugs (mechanisms).
Course Methods and Techniques	Lectures, particular talks by prominent scientists, quizzes, patient cases, articles will be included within the course content. Additionally, each student (as an individual or within groups ) is responsible from presenting an article in front of the class.
Prerequisites and co-requisities	None
Course Coordinator	None
Name of Lecturers	Asist Prof.Dr. Nurettin AYVALI nurettin.ayvali@agu.edu.tr
Assistants	None
Work Placement(s)	No

Recommended or Required Reading

Resources
	Lectures and some of the notes (on papers) would be shared.
	Canvas

	Canvas announcement

Planned Learning Activities and Teaching Methods

Activities are given in detail in the section of "Assessment Methods and Criteria" and "Workload Calculation"

Assessment Methods and Criteria

In-Term Studies	Quantity	Percentage
Yarıl yılSonu Sınavı/Dönem Projesinin Başarı Notuna Katkısı	1	% 20
Quiz/Küçük Sınav	7	% 30
Sunum/Seminer	1	% 20
Final examination	1	% 20
Total	10	% 90

ECTS Allocated Based on Student Workload

Activities	Quantity	Duration	Total Work Load
Yazılı Sınav	1	2	2
Grup Sunumu	1	2	2
Ders Dışı Sınav	4	3	12
Sunum için Hazırlık	1	15	15
Sunum	1	2	2
Kısa Sınav	6	1	6
Okuma	12	2	24
Kişisel Çalışma	10	4	40
Yüz Yüze Ders	1	2	2
Ders Dışı Ara Sınav	1	3	3
Derse Devam	14	3	42
Final Sınavı	1	3	3
Total Work Load			Number of ECTS Credits 5 153

Course Learning Outcomes: Upon the successful completion of this course, students will be able to:

No	Learning Outcomes
1	To develop perspective in molecular medicine, enabling students to grasp relationship between a disease and drug's mechanism (at cellular and/or organismic levels).
2	To expand the knowledge on disease pathophysiology, and particularly using cancer as a model (reference).
3	To cultivate interest in biomarker-based novel (and/or recently approved) drugs, since medicine is becoming more and more personalised.

Weekly Detailed Course Contents

Week	Topics	Study Materials	Materials
1	Introduction into Molecular Medicine and Personalised Medicine
2	Major problems of the Modern Medicine
3	Personalised medicine: Infant/62 year old died/affected due to undiagnosed pharmacogenetic marker (two papers/cases)
4	Keytruda: It was the first time that FDA approved a drug not based on cancer origin/site, but on biomarkers & (immunotherapy)
5	Patisiran: It was the first time that FDA approved a drug which shows RNA-interference (RNAi) pathway is druggable
6	Casgevy: It was the first time that FDA approved a CRISPR based therapy (sickle cell & thalessemia)
7	Midterm
8	Lecture-free week
9	Economic Burden of Cancer (potential productive life lost...) Hallmarks and Enabling Characteristics (Weinberg & Hanahan)
10	Tumor micro environment, TME (accessories to the crime) Dysregulated apoptotic components/mechanisms in cancer
11	Nonmutational epigenetic reprogramming plays role in the carcinogenesis.
12	Use of induced Pluripotent Stem Cells and proof of concept example for gene therapy for disease treatment (sickle cell disease in a mouse model)
13	CRISPR loss-of-function libraries are being used to understand mechanisms of 'drug metabolism and/or resistance' (Cytarabine & Venetoclax (BCL2-inhibitor)).
14	Ethical Considerations & "Article" Reading, Analysis, Interpreting, Impacts and Limitations, Presenting ...

Recommended Optional Programme Components

Veri yok

Contribution of Learning Outcomes to Programme Outcomes

Contribution: 1: Very Slight 2:Slight 3:Moderate 4:Significant 5:Very Significant

https://sis.agu.edu.tr/oibs/bologna/progCourseDetails.aspx?curCourse=71990&lang=en